{"id":"octohydroaminoacridine-succinate","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Cholinergic side effects"}]},"_chembl":{"chemblId":"CHEMBL4297411","moleculeType":"Small molecule","molecularWeight":"320.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug belongs to the acridine class of compounds, which are known acetylcholinesterase inhibitors. By blocking the enzyme that breaks down acetylcholine, it increases cholinergic neurotransmission in the central nervous system, potentially improving cognitive function and memory. This mechanism is similar to other cognitive enhancers used in neurodegenerative diseases.","oneSentence":"Octohydroaminoacridine succinate is a cognitive enhancer that likely increases acetylcholine levels in the brain by inhibiting acetylcholinesterase.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:23:54.321Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cognitive impairment or dementia (likely indication based on mechanism and phase 3 status)"}]},"trialDetails":[{"nctId":"NCT03283059","phase":"PHASE3","title":"Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2017-08-16","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT01569516","phase":"PHASE2","title":"Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease","status":"UNKNOWN","sponsor":"Changchun Huayang High-tech Co., Ltd","startDate":"2011-06","conditions":"Alzheimer's Disease","enrollment":288}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Octohydroaminoacridine Succinate","genericName":"Octohydroaminoacridine Succinate","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Octohydroaminoacridine succinate is a cognitive enhancer that likely increases acetylcholine levels in the brain by inhibiting acetylcholinesterase. Used for Cognitive impairment or dementia (likely indication based on mechanism and phase 3 status).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}